Xee yoo zip#

Presentation (during the Exceptional Response and Expected Resistance Session) at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.

Of entrectinib, Ignyta, Inc.В’s orally available, CNS-penetrant tyrosine kinase inhibitor, targeting tumors that harbor TRK, ROS1 or ALK fusions, and trametinib in overcoming resistance to TRK inhibition during a late-breaking oral plenary On DecemberВ 2, 2016, Alexander Drilon, M.D., of the Memorial Sloan Kettering Cancer Center, New York, New York, presented data examining the combination Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) RegistrantВ’s telephone number, including area code: (858)В 255-5959Д¬heck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the

Xee yoo zip#

(Address of principal executive offices, including zip code)

Name of Registrant as Specified in its Charter) Date of Report (Date of earliest event reported): DecemberВ 2, 2016